DeCure for Adult acute respiratory distress syndrome
DeCure's autonomous Respiratory AI scientist is researching a drug-repurposing hypothesis for adult acute respiratory distress syndrome — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAdult acute respiratory distress syndrome maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedIloprostApproved drugapprovedEpoprostenolApproved drug
Structures already discussed alongside adult acute respiratory distress syndrome in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
complement C5 (C5) — C5 is one of the genes in this disease's Open Targets module — part of the target space DeCure's repurposing candidates point at. The protein backbone is drawn as a cartoon. The structure has ethanol bound in it, shown as sticks.
Loading structure…
helix sheet eohdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7AD7 · 2.3 Å · ligand ETHANOL (EOH). Experimental structure, not a prediction.
What the evidence adds up to
A 2012 review reports that the fatality rate of acute respiratory distress syndrome (ARDS) in adults, though decreased during the 1990s, still exceeds 30%. Management remains supportive, focused on improving gas exchange and preventing complications while treating the underlying disease. The same review states that novel drugs studied as potential ARDS-specific therapies have not been shown to improve clinical outcome and cannot be recommended for routine care. A 2014 review notes that despite steady improvement in outcomes over three decades, ARDS remains a common cause of morbidity and mortality in adult intensive care units, and that numerous multi-centre clinical trials have attempted to translate smaller studies into wider practice.
A 2010 review of rescue therapies for severe ARDS describes several interventions—recruitment maneuvers, high positive end-expiratory pressure, prone position, high-frequency oscillatory ventilation, glucocorticoids, inhaled nitric oxide, buffer therapy, and extracorporeal life support—but offers no single drug as a proven treatment. A 1980 case report describes a single instance of intravenous Placidyl (ethchlorvynol) injection leading to ARDS, with a documented response to positive end-expiratory pressure therapy; this is not a therapeutic trial. A 2017 German-language review states that despite progress in research and therapy, lethality remains unacceptably high, and that numerous pharmacological approaches have been investigated in past decades without a breakthrough.
No drug has been shown in these abstracts to reduce mortality in adult ARDS in a controlled trial. The evidence consists of reviews noting the failure of novel pharmacological agents to improve clinical outcome, and descriptions of supportive or rescue interventions that are not drug-based. What is still missing is a drug that demonstrates a survival benefit in adequately powered, randomised trials, along with clearer patient stratification to identify who might respond, and sustained funding for such trials rather than repeated negative studies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Critical Care Medicine · 2010 · 171 citations · open access
Therapeutic strategies for severe acute lung injury
AbstractOBJECTIVE: In the management of patients with severe acute lung injury and acute respiratory distress syndrome, clinicians are sometimes challenged to maintain acceptable gas exchange while avoiding harmful mechanical ventilation practices. In some of these patients, physicians may consider the use of "rescue therapies" to sustain life. Our goal is to provide a practical, evidence-based review to assist critical care physicians' care for patients with severe acute lung injury and acute respiratory distress syndrome. DATA SOURCES: We searched the PubMed database for clinical trials that examined the use of the following therapies in severe acute lung injury and acute respiratory distress syndrome: recruitment maneuvers, high positive end-expiratory pressure, prone position, high-frequency oscillatory ventilation, glucocorticoids, inhaled nitric oxide, buffer therapy, and extracorporeal life support. STUDY SELECTION: All clinical trials that included patients with severe acute lung injury and acute respiratory distress syndrome were included in the review. DATA SYNTHESIS: The primary author reviewed the aforementioned trials in depth and then disputed findings and conclusions with the other authors until consensus was achieved. CONCLUSIONS: This article is designed to provide clinicians with a simple bedside definition for the diagnosis of severe acute respiratory distress syndrome; to describe several therapies that can be used for severe acute respiratory distress syndrome with an emphasis on the potential risks and the indications and benefits; and to offer practical guidelines for implementation of these therapies.
Adult respiratory distress syndrome after Placidyl abuse
AbstractA case of intravenous Placidyl injection is described which resulted in pulmonary pathophysiology consistent with adult respiratory distress syndrome (ARDS). Concise documentation of pulmonary and hemodynamic function demonstrated the dramatic response to PEEP therapy. Previously reported cases, mechanisms, and similarity to heroin-induced ARDS are discussed.
DMW - Deutsche Medizinische Wochenschrift · 2017 · 3 citations
ARDS: Adjunktive medikamentöse Therapie
AbstractAcute respiratory distress syndrome (ARDS) is still regarded as an enormous medical challenge due to its complexity and poor prognosis. In spite of progress in research and therapy lethality remains unacceptably high. Besides established interventiotnal treatment options, numerous pharmacological approaches have been investigated in the past decades.
The Pharmacology of Acute Respiratory Distress Syndrome
AbstractAcute Respiratory Distress Syndrome (ARDS) is a common respiratory complication of critical severe illness or injury. Despite steady improvement in outcomes over the last three decades, ARDS remains a common cause of morbidity and mortality in pediatric and adult intensive care units. Due to its extensive burden, ARDS has been the focus of numerous multi-center clinical trials which have attempted to translate animal, ex vivo, and small single center studies into wider practice. Since the results of several of these large studies have been recently published, we sought to review the pharmacology of ARDS, summarize the major non-pharmacologic interventions shown to improve outcome, and update the reader on evolving therapies which may enter clinical practice in the coming decade.
Novel chemotherapies for acute respiratory distress syndrome
AbstractThe fatality rate of acute respiratory distress syndrome (ARDS) has decreased during the 1990s but still exceeds 30％.Management of ARDS is supportive,aimed at improving gas exchange and preventing complications while the underlying disease that precipitated ARDS is treated.Novel drugs which were as potential ARDS specific therapies have been studied.However,they have not been shown to improve clinical outcome and,thus,cannot be recommended for routine care.
Key words:
Acute respiratory distress syndrome; Novel drug
Therapeutic iloprost for the treatment of acute respiratory distress syndrome (ARDS) (the ThIlo trial): a prospective, randomized, multicenter phase II study
AbstractAbstract Background Acute respiratory distress syndrome (ARDS) is caused by rapid-onset (within hours) acute inflammatory processes in lung tissue, and it is a life-threatening condition with high mortality. The treatment of ARDS to date is focused on the prevention of further iatrogenic damage of the lung rather than the treatment of the initial inflammatory process. Several preclinical studies have revealed a beneficial effect of iloprost on the control of pulmonary inflammation, and in a small number of patients with ARDS, iloprost treatment resulted in improved oxygenation. Therefore, we plan to conduct a large multicenter trial to evaluate the effect of iloprost on ARDS. Methods The Therapeutic Iloprost during ARDS trial (ThIlo trial) is a multicenter, randomized, single blinded, clinical phase II trial assessing the efficacy of inhaled iloprost for the prevention of the development and progression of ARDS in critically ill patients. One hundred fifty critically ill patients suffering from acute ARDS will be treated either by nebulized iloprost or NaCl 0.9% for 5 days. Blood samples will be drawn at defined time points to elucidate the serum levels of iloprost and inflammatory markers during treatment. Mechanical ventilation will be standardized. In follow-up visits at days 28 and 90 as well as 6 months after enrollment, functional status according to the Barthel Index and a health care-related questionnaire, and frailty (Vulnerable Elders Survey) will be evaluated. The primary endpoint is the improvement of oxygenation, defined as the ratio of PaO2/FiO2. Secondary endpoints include 90-day all-cause mortality, Sequential Organ Failure Assessment scores during the study period up to day 90, the duration of mechanical ventilation, the length of intensive care unit (ICU) stay, ventilator-associated pneumonia, delirium, ICU-acquired weakness, and discharge localization. The study will be conducted in three university ARDS centers in Germany. Discussion The results of the ThIlo trial will highlight the anti-inflammatory effect of iloprost on early inflammatory processes during ARDS, resulting in the improvement of outcome parameters in patients with ARDS. Trial registration EUDRA-CT: 2016-003168-37. Registered on 12 April 2017. ClinicalTrials.gov: NCT03111212. Registered on 4 June 2017.
sj-docx-1-aop-10.1177_10600280211069182 – Supplemental material for Evaluation of Continuous Inhaled Epoprostenol in the Treatment of Acute Respiratory Distress Syndrome, Including Patients With SARS-CoV-2 Infection
AbstractSupplemental material, sj-docx-1-aop-10.1177_10600280211069182 for Evaluation of Continuous Inhaled Epoprostenol in the Treatment of Acute Respiratory Distress Syndrome, Including Patients With SARS-CoV-2 Infection by Hannah L. Niss, Adham Mohamed, Timothy P. Berry, Timothy M. Saettele, Michelle M. Haines and Elizabeth L. Thomas in Annals of Pharmacotherapy
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
